The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles:
Related suggestion:
13th National Women's Congress opens in BeijingSenior CPC official pledges support for Chinese language to go globalMan City earns big win over Luton despite rotating squad. Newcastle routs Tottenham at home againGoalie error costs relegation battler Burnley a draw with Brighton in EPLA Michigan man and his dog are rescued from an inland lake's icy watersChinese premier stresses nurturing new drivers for highXi's Shanghai inspection tour sends signal of highSenior CPC official stresses addressing people's immediate concernsSenior CPC official calls for improving science popularizationChinese premier urges redoubled efforts to combat corruption in government
2.538s , 6516.375 kb
Copyright © 2024 Powered by It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start? ,Global Grandstand news portal